ID   GLSK_HUMAN              Reviewed;         669 AA.
AC   O94925; Q9UL05; Q9UL06; Q9UL07; Q9UN40;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   10-MAY-2017, entry version 173.
DE   RecName: Full=Glutaminase kidney isoform, mitochondrial;
DE            Short=GLS;
DE            EC=3.5.1.2;
DE   AltName: Full=K-glutaminase;
DE   AltName: Full=L-glutamine amidohydrolase;
DE   Flags: Precursor;
GN   Name=GLS; Synonyms=GLS1, KIAA0838;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, AND
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Placenta;
RX   PubMed=11015561;
RA   Elgadi K.M., Meguid R.A., Qian M., Souba W.W., Abcouwer S.F.;
RT   "Cloning and analysis of unique human glutaminase isoforms generated
RT   by tissue-specific alternative splicing.";
RL   Physiol. Genomics 1:51-62(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Chavez R.A., Wang C., Cong R., Hawkinson J.E., Forsayeth J.R.;
RT   "Identification and expression of human renal and hepatic glutaminase
RT   isoforms.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10719215; DOI=10.1016/S0169-328X(99)00331-9;
RA   Holcomb T., Taylor L., Trohkimoinen J., Curthoys N.P.;
RT   "Isolation, characterization and expression of a human brain
RT   mitochondrial glutaminase cDNA.";
RL   Brain Res. Mol. Brain Res. 76:56-63(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 225-466.
RC   TISSUE=Colon carcinoma;
RA   Turner A., McGivan J.D.;
RT   "Adenoma and carcinoma cell lines derived from colorectal tumours
RT   express different isoforms of glutaminase.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [8]
RP   INTERACTION WITH ATCAY, AND SUBCELLULAR LOCATION.
RX   PubMed=16899818; DOI=10.1242/jcs.03061;
RA   Buschdorf J.P., Li Chew L., Zhang B., Cao Q., Liang F.Y., Liou Y.C.,
RA   Zhou Y.T., Low B.C.;
RT   "Brain-specific BNIP-2-homology protein Caytaxin relocalises
RT   glutaminase to neurite terminals and reduces glutamate levels.";
RL   J. Cell Sci. 119:3337-3350(2006).
RN   [9]
RP   TISSUE SPECIFICITY (ISOFORM 1 AND ISOFORM 3).
RX   PubMed=17940881; DOI=10.1007/s11064-007-9507-6;
RA   Szeliga M., Matyja E., Obara M., Grajkowska W., Czernicki T.,
RA   Albrecht J.;
RT   "Relative expression of mRNAs coding for glutaminase isoforms in CNS
RT   tissues and CNS tumors.";
RL   Neurochem. Res. 33:808-813(2008).
RN   [10]
RP   IDENTIFICATION.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-311, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22228304; DOI=10.1073/pnas.1112495109;
RA   Cassago A., Ferreira A.P., Ferreira I.M., Fornezari C., Gomes E.R.,
RA   Greene K.S., Pereira H.M., Garratt R.C., Dias S.M., Ambrosio A.L.;
RT   "Mitochondrial localization and structure-based phosphate activation
RT   mechanism of glutaminase C with implications for cancer metabolism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:1092-1097(2012).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 71-550 (ISOFORM 3) IN
RP   COMPLEXES WITH GLUTAMATE AND SYNTHETIC INHIBITOR BPTES, PROTEIN
RP   SEQUENCE OF N-TERMINUS, CATALYTIC ACTIVITY, MUTAGENESIS OF PHE-318;
RP   PHE-322 AND TYR-394, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBUNIT.
RX   PubMed=22049910; DOI=10.1021/bi201613d;
RA   DeLaBarre B., Gross S., Fang C., Gao Y., Jha A., Jiang F., Song J.J.,
RA   Wei W., Hurov J.B.;
RT   "Full-length human glutaminase in complex with an allosteric
RT   inhibitor.";
RL   Biochemistry 50:10764-10770(2011).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 221-533 IN COMPLEX WITH
RP   GLUTAMATE.
RG   Structural genomics consortium (SGC);
RT   "Human glutaminase in complex with L-glutamate.";
RL   Submitted (JUL-2011) to the PDB data bank.
CC   -!- FUNCTION: Catalyzes the first reaction in the primary pathway for
CC       the renal catabolism of glutamine. Plays a role in maintaining
CC       acid-base homeostasis. Regulates the levels of the
CC       neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic
CC       activity.
CC   -!- CATALYTIC ACTIVITY: L-glutamine + H(2)O = L-glutamate + NH(3).
CC       {ECO:0000269|PubMed:22049910}.
CC   -!- ENZYME REGULATION: Isoform 1 and isoform 3 are activated by
CC       phosphate. Inhibited by BPTES. BPTES binds between subunits and
CC       favors dissociation of the tetramer into dimers.
CC       {ECO:0000269|PubMed:22049910}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.9 mM for glutamine (isoform 1)
CC         {ECO:0000269|PubMed:22049910};
CC         KM=1.4 mM for glutamine (isoform 3)
CC         {ECO:0000269|PubMed:22049910};
CC   -!- SUBUNIT: Heterotetramer. Interacts with ATCAY; the interaction is
CC       direct and may control GLS localization, negatively regulating its
CC       activity. {ECO:0000269|PubMed:16899818,
CC       ECO:0000269|PubMed:22049910, ECO:0000269|Ref.17}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm, cytosol.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Mitochondrion.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=KGA;
CC         IsoId=O94925-1; Sequence=Displayed;
CC       Name=2; Synonyms=GAM;
CC         IsoId=O94925-2; Sequence=VSP_001765, VSP_001766;
CC       Name=3; Synonyms=Glutaminase C, GAC;
CC         IsoId=O94925-3; Sequence=VSP_001767;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 3 are detected in brain
CC       cortex. Isoform 3 is highly expressed in astrocytoma,
CC       ganglioglioma and ependymoma. Isoform 1 is highly expressed in
CC       brain and kidney, but not detected in liver. Isoform 3 is highly
CC       expressed in heart and pancreas, detected at lower levels in
CC       placenta, lung, pancreas and kidney, but is not detected in liver.
CC       Isoform 2 is expressed in cardiac and skeletal muscle.
CC       {ECO:0000269|PubMed:11015561}.
CC   -!- SIMILARITY: Belongs to the glutaminase family. {ECO:0000305}.
CC   -!- CAUTION: Isoform 3 is predicted to be expressed at very low levels
CC       due to a premature stop codon in the mRNA, leading to nonsense-
CC       mediated mRNA decay (PubMed:14759258), but has been shown to be
CC       well expressed (PubMed:17940881 and PubMed:11015561) and the
CC       encoded protein is detected in mitochondria (PubMed:22228304).
CC       {ECO:0000305|PubMed:14759258, ECO:0000305|PubMed:22228304}.
CC   -!- CAUTION: A report observed N-glycosylation at Asn-620
CC       (PubMed:19139490). However, as the protein is mitochondrial,
CC       additional evidences are required to confirm this result.
CC       {ECO:0000305|PubMed:19139490}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA74861.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF158555; AAD47056.1; -; mRNA.
DR   EMBL; AF097492; AAF00088.1; -; mRNA.
DR   EMBL; AF097493; AAF00089.1; -; mRNA.
DR   EMBL; AF097495; AAF00090.1; -; mRNA.
DR   EMBL; AB020645; BAA74861.2; ALT_INIT; mRNA.
DR   EMBL; AF223943; AAF33825.1; -; mRNA.
DR   EMBL; AF327434; AAG47842.1; -; mRNA.
DR   EMBL; BC038507; AAH38507.2; -; mRNA.
DR   EMBL; AF279697; AAG17700.1; -; mRNA.
DR   CCDS; CCDS2308.1; -. [O94925-1]
DR   CCDS; CCDS58744.1; -. [O94925-3]
DR   RefSeq; NP_001243239.1; NM_001256310.1. [O94925-3]
DR   RefSeq; NP_055720.3; NM_014905.4. [O94925-1]
DR   UniGene; Hs.116448; -.
DR   UniGene; Hs.737608; -.
DR   PDB; 3CZD; X-ray; 2.40 A; A=221-533.
DR   PDB; 3UNW; X-ray; 2.56 A; A/B/C/D=71-597.
DR   PDB; 3UO9; X-ray; 2.30 A; A/B/C/D=71-597.
DR   PDB; 3VOY; X-ray; 2.20 A; A=221-533.
DR   PDB; 3VOZ; X-ray; 2.40 A; A=221-533.
DR   PDB; 3VP0; X-ray; 2.40 A; A=221-533.
DR   PDB; 3VP1; X-ray; 2.30 A; A=221-533.
DR   PDB; 3VP2; X-ray; 2.70 A; A=221-533.
DR   PDB; 3VP3; X-ray; 2.70 A; A=221-533.
DR   PDB; 3VP4; X-ray; 2.45 A; A=221-533.
DR   PDB; 4O7D; X-ray; 2.30 A; A=221-531.
DR   PDB; 5D3O; X-ray; 2.79 A; A/B=72-597.
DR   PDB; 5FI2; X-ray; 2.50 A; A/B/C/D=72-597.
DR   PDB; 5FI6; X-ray; 2.52 A; A/B/C/D=72-597.
DR   PDB; 5FI7; X-ray; 2.50 A; A/B/C/D=72-597.
DR   PDB; 5HL1; X-ray; 2.40 A; A/B/C/D=72-597.
DR   PDB; 5I94; X-ray; 2.98 A; A/B/C/D=72-597.
DR   PDB; 5JYO; X-ray; 2.10 A; A/B/C/D/E/F/G/H=221-533.
DR   PDB; 5JYP; X-ray; 2.74 A; A=221-533.
DR   PDBsum; 3CZD; -.
DR   PDBsum; 3UNW; -.
DR   PDBsum; 3UO9; -.
DR   PDBsum; 3VOY; -.
DR   PDBsum; 3VOZ; -.
DR   PDBsum; 3VP0; -.
DR   PDBsum; 3VP1; -.
DR   PDBsum; 3VP2; -.
DR   PDBsum; 3VP3; -.
DR   PDBsum; 3VP4; -.
DR   PDBsum; 4O7D; -.
DR   PDBsum; 5D3O; -.
DR   PDBsum; 5FI2; -.
DR   PDBsum; 5FI6; -.
DR   PDBsum; 5FI7; -.
DR   PDBsum; 5HL1; -.
DR   PDBsum; 5I94; -.
DR   PDBsum; 5JYO; -.
DR   PDBsum; 5JYP; -.
DR   ProteinModelPortal; O94925; -.
DR   SMR; O94925; -.
DR   BioGrid; 109006; 41.
DR   DIP; DIP-50591N; -.
DR   IntAct; O94925; 3.
DR   MINT; MINT-4096121; -.
DR   STRING; 9606.ENSP00000317379; -.
DR   BindingDB; O94925; -.
DR   ChEMBL; CHEMBL2146302; -.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   DrugBank; DB00130; L-Glutamine.
DR   GuidetoPHARMACOLOGY; 2891; -.
DR   iPTMnet; O94925; -.
DR   PhosphoSitePlus; O94925; -.
DR   SwissPalm; O94925; -.
DR   BioMuta; GLS; -.
DR   EPD; O94925; -.
DR   MaxQB; O94925; -.
DR   PaxDb; O94925; -.
DR   PeptideAtlas; O94925; -.
DR   PRIDE; O94925; -.
DR   TopDownProteomics; O94925-2; -. [O94925-2]
DR   DNASU; 2744; -.
DR   Ensembl; ENST00000320717; ENSP00000317379; ENSG00000115419. [O94925-1]
DR   Ensembl; ENST00000338435; ENSP00000340689; ENSG00000115419. [O94925-3]
DR   GeneID; 2744; -.
DR   KEGG; hsa:2744; -.
DR   UCSC; uc002use.4; human. [O94925-1]
DR   CTD; 2744; -.
DR   DisGeNET; 2744; -.
DR   GeneCards; GLS; -.
DR   H-InvDB; HIX0161645; -.
DR   HGNC; HGNC:4331; GLS.
DR   HPA; HPA036223; -.
DR   MIM; 138280; gene.
DR   neXtProt; NX_O94925; -.
DR   OpenTargets; ENSG00000115419; -.
DR   PharmGKB; PA28734; -.
DR   eggNOG; KOG0506; Eukaryota.
DR   eggNOG; COG2066; LUCA.
DR   GeneTree; ENSGT00390000010463; -.
DR   HOGENOM; HOG000216891; -.
DR   HOVERGEN; HBG005856; -.
DR   InParanoid; O94925; -.
DR   KO; K01425; -.
DR   OMA; FMNKMAG; -.
DR   OrthoDB; EOG091G03YU; -.
DR   PhylomeDB; O94925; -.
DR   TreeFam; TF313359; -.
DR   BRENDA; 3.5.1.2; 2681.
DR   Reactome; R-HSA-210500; Glutamate Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-70614; Amino acid synthesis and interconversion (transamination).
DR   SABIO-RK; O94925; -.
DR   ChiTaRS; GLS; human.
DR   EvolutionaryTrace; O94925; -.
DR   GenomeRNAi; 2744; -.
DR   PRO; PR:O94925; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000115419; -.
DR   CleanEx; HS_GLS; -.
DR   ExpressionAtlas; O94925; baseline and differential.
DR   Genevisible; O94925; HS.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0004359; F:glutaminase activity; IDA:UniProtKB.
DR   GO; GO:0008652; P:cellular amino acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0007268; P:chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0006537; P:glutamate biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0014047; P:glutamate secretion; TAS:Reactome.
DR   GO; GO:0006543; P:glutamine catabolic process; IDA:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   GO; GO:0002087; P:regulation of respiratory gaseous exchange by neurological system process; IEA:Ensembl.
DR   GO; GO:0001967; P:suckling behavior; IEA:Ensembl.
DR   Gene3D; 1.25.40.20; -; 1.
DR   HAMAP; MF_00313; Glutaminase; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR012338; Beta-lactam/transpept-like.
DR   InterPro; IPR015868; Glutaminase.
DR   PANTHER; PTHR12544; PTHR12544; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF04960; Glutaminase; 1.
DR   SMART; SM00248; ANK; 2.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF56601; SSF56601; 1.
DR   TIGRFAMs; TIGR03814; Gln_ase; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ANK repeat;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Hydrolase;
KW   Mitochondrion; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transit peptide.
FT   TRANSIT       1     16       Mitochondrion. {ECO:0000250}.
FT   CHAIN        17    669       Glutaminase kidney isoform,
FT                                mitochondrial.
FT                                /FTId=PRO_0000011622.
FT   REPEAT      585    614       ANK 1.
FT   REPEAT      619    648       ANK 2.
FT   BINDING     286    286       Substrate.
FT   BINDING     335    335       Substrate.
FT   BINDING     381    381       Substrate.
FT   BINDING     388    388       Substrate.
FT   BINDING     414    414       Substrate.
FT   BINDING     466    466       Substrate.
FT   BINDING     484    484       Substrate; via amide nitrogen.
FT   MOD_RES     130    130       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:D3Z7P3}.
FT   MOD_RES     164    164       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:D3Z7P3}.
FT   MOD_RES     311    311       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     652    652       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P13264}.
FT   VAR_SEQ     162    169       ALKSTGLR -> VSFYIFLS (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_001765.
FT   VAR_SEQ     170    669       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_001766.
FT   VAR_SEQ     551    669       VKSVINLLFAAYTGDVSALRRFALSAMDMEQRDYDSRTALH
FT                                VAAAEGHVEVVKFLLEACKVNPFPKDRWNNTPMDEALHFGH
FT                                HDVFKILQEYQVQYTPQGDSDNGKENQTVHKNLDGLL ->
FT                                HSFGPLDYESLQQELALKETVWKKVSPESNEDISTTVVYRM
FT                                ESLGEKS (in isoform 3).
FT                                {ECO:0000303|PubMed:11015561}.
FT                                /FTId=VSP_001767.
FT   VARIANT     254    254       A -> P (in dbSNP:rs16833035).
FT                                /FTId=VAR_049188.
FT   MUTAGEN     318    318       F->Y: No effect on catalytic activity.
FT                                Loss of inhibition by BPTES; when
FT                                associated with S-322.
FT                                {ECO:0000269|PubMed:22049910}.
FT   MUTAGEN     322    322       F->S: No effect on catalytic activity.
FT                                Loss of inhibition by BPTES; when
FT                                associated with Y-318.
FT                                {ECO:0000269|PubMed:22049910}.
FT   MUTAGEN     394    394       Y->L: No effect on catalytic activity.
FT                                Loss of inhibition by BPTES.
FT                                {ECO:0000269|PubMed:22049910}.
FT   CONFLICT      6      6       G -> S (in Ref. 1; AAF00090).
FT                                {ECO:0000305}.
FT   CONFLICT     66     66       E -> D (in Ref. 1; AAF00090).
FT                                {ECO:0000305}.
FT   CONFLICT    219    219       F -> L (in Ref. 4; AAG47842).
FT                                {ECO:0000305}.
FT   CONFLICT    268    268       V -> A (in Ref. 1; AAD47056).
FT                                {ECO:0000305}.
FT   HELIX       139    148       {ECO:0000244|PDB:3UO9}.
FT   STRAND      152    155       {ECO:0000244|PDB:3UO9}.
FT   HELIX       156    165       {ECO:0000244|PDB:3UO9}.
FT   HELIX       173    175       {ECO:0000244|PDB:3UO9}.
FT   HELIX       176    188       {ECO:0000244|PDB:3UO9}.
FT   STRAND      194    196       {ECO:0000244|PDB:5D3O}.
FT   HELIX       197    204       {ECO:0000244|PDB:3UO9}.
FT   HELIX       205    207       {ECO:0000244|PDB:3UO9}.
FT   HELIX       208    216       {ECO:0000244|PDB:3UO9}.
FT   STRAND      219    223       {ECO:0000244|PDB:3UO9}.
FT   HELIX       224    239       {ECO:0000244|PDB:5JYO}.
FT   STRAND      244    246       {ECO:0000244|PDB:5JYO}.
FT   HELIX       251    254       {ECO:0000244|PDB:5JYO}.
FT   STRAND      262    267       {ECO:0000244|PDB:5JYO}.
FT   STRAND      272    277       {ECO:0000244|PDB:5JYO}.
FT   HELIX       285    287       {ECO:0000244|PDB:5JYO}.
FT   HELIX       288    300       {ECO:0000244|PDB:5JYO}.
FT   HELIX       302    305       {ECO:0000244|PDB:5JYO}.
FT   TURN        306    308       {ECO:0000244|PDB:5JYO}.
FT   STRAND      315    317       {ECO:0000244|PDB:3VOY}.
FT   STRAND      327    330       {ECO:0000244|PDB:5JYP}.
FT   HELIX       335    344       {ECO:0000244|PDB:5JYO}.
FT   TURN        345    348       {ECO:0000244|PDB:5JYO}.
FT   HELIX       351    365       {ECO:0000244|PDB:5JYO}.
FT   TURN        366    368       {ECO:0000244|PDB:5JYO}.
FT   STRAND      371    373       {ECO:0000244|PDB:5JYO}.
FT   HELIX       375    384       {ECO:0000244|PDB:5JYO}.
FT   HELIX       386    397       {ECO:0000244|PDB:5JYO}.
FT   HELIX       407    418       {ECO:0000244|PDB:5JYO}.
FT   STRAND      420    422       {ECO:0000244|PDB:5JYO}.
FT   HELIX       424    435       {ECO:0000244|PDB:5JYO}.
FT   TURN        436    438       {ECO:0000244|PDB:5JYO}.
FT   TURN        441    443       {ECO:0000244|PDB:5JYO}.
FT   HELIX       450    463       {ECO:0000244|PDB:5JYO}.
FT   HELIX       466    468       {ECO:0000244|PDB:5JYO}.
FT   HELIX       469    475       {ECO:0000244|PDB:5JYO}.
FT   STRAND      480    482       {ECO:0000244|PDB:5JYO}.
FT   STRAND      486    492       {ECO:0000244|PDB:5JYO}.
FT   TURN        493    495       {ECO:0000244|PDB:5JYO}.
FT   STRAND      496    501       {ECO:0000244|PDB:5JYO}.
FT   STRAND      503    505       {ECO:0000244|PDB:5JYO}.
FT   STRAND      509    511       {ECO:0000244|PDB:5JYO}.
FT   HELIX       512    525       {ECO:0000244|PDB:5JYO}.
SQ   SEQUENCE   669 AA;  73461 MW;  4E5E63505E84E0B7 CRC64;
     MMRLRGSGML RDLLLRSPAG VSATLRRAQP LVTLCRRPRG GGRPAAGPAA AARLHPWWGG
     GGWPAEPLAR GLSSSPSEIL QELGKGSTHP QPGVSPPAAP AAPGPKDGPG ETDAFGNSEG
     KELVASGENK IKQGLLPSLE DLLFYTIAEG QEKIPVHKFI TALKSTGLRT SDPRLKECMD
     MLRLTLQTTS DGVMLDKDLF KKCVQSNIVL LTQAFRRKFV IPDFMSFTSH IDELYESAKK
     QSGGKVADYI PQLAKFSPDL WGVSVCTVDG QRHSTGDTKV PFCLQSCVKP LKYAIAVNDL
     GTEYVHRYVG KEPSGLRFNK LFLNEDDKPH NPMVNAGAIV VTSLIKQGVN NAEKFDYVMQ
     FLNKMAGNEY VGFSNATFQS ERESGDRNFA IGYYLKEKKC FPEGTDMVGI LDFYFQLCSI
     EVTCESASVM AATLANGGFC PITGERVLSP EAVRNTLSLM HSCGMYDFSG QFAFHVGLPA
     KSGVAGGILL VVPNVMGMMC WSPPLDKMGN SVKGIHFCHD LVSLCNFHNY DNLRHFAKKL
     DPRREGGDQR VKSVINLLFA AYTGDVSALR RFALSAMDME QRDYDSRTAL HVAAAEGHVE
     VVKFLLEACK VNPFPKDRWN NTPMDEALHF GHHDVFKILQ EYQVQYTPQG DSDNGKENQT
     VHKNLDGLL
//
